StratDeck

Two stocks in Healthcare

Lonza Group vs Sanofi: profit, growth, debt and price compared

Sanofi is stronger on 5 of 7 figures: profit margin, sales growth, debt, price for its expected profit and dividend. Lonza Group is stronger on 1: price trend.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Lonza Group and Sanofi side by side
Lonza GroupLONN.SWSanofiSAN.PA
Net margin−1.6%Stronger: 8.2%
Revenue growth, past year+11.20%Stronger: +15.70%
Debt to equity51.1%Stronger: 27.1%
Forward P/E29.7×Stronger: 9.1×
Dividend yield0.75%Stronger: 4.66%
AnalystsBuy · 23Buy · 23
From its 200-day averageStronger: +17.8%+12.2%

Share price over the past year

  • Lonza Group+24.6%
  • Sanofi−0.1%

21 Nov 202518 Nov 2026

Lonza Group or Sanofi: which is stronger?

  • SAN.PA

    Which is more profitable?

    Sanofi keeps more of each sale as profit: 8.2% against −1.6%.

  • SAN.PA

    Which is growing its sales faster?

    Sanofi is growing its sales faster: +15.70% over the past year, against +11.20%.

  • SAN.PA

    Which has borrowed less?

    Sanofi has borrowed less: its debt is 27.1% of what its shareholders own, against 51.1% for Lonza Group.

  • SAN.PA

    Which costs less for the profit it is expected to make?

    Sanofi costs less for the profit it is expected to make: 9.1× its forward earnings, against 29.7×.

  • SAN.PA

    Which pays more in dividends?

    Sanofi pays more back in dividends for what a share costs: 4.66% a year, against 0.75%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • LONN.SW

    Which is in the stronger price trend?

    Lonza Group's price is in the stronger trend: 17.8% above its 200-day average, against 12.2% above.

What each company does

LONN.SWLonza Group

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, and internationally.

Reports results on 27 January 2027

SAN.PASanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.

Reports results on 28 January 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.